

Upadacitinib for treating active non-radiographic axial spondyloarthritis

Information for the public

Published: 1 February 2023

www.nice.org.uk

Upadacitinib (Rinvoq) is available on the NHS as a possible treatment for active non-radiographic axial spondyloarthritis with inflammation (shown by a blood test or MRI) in adults if:

- the condition has a Bath Ankylosing Spondylitis Disease Activity Index score of 4 units or more and a spinal visual analogue scale of 4 cm or more
- it is not controlled well enough with non-steroidal anti-inflammatory drugs, and
- tumour necrosis factor-alpha inhibitors are not suitable or have not worked well enough.

Treatment should be stopped after 16 weeks if it is not working well enough.

If you are not eligible for upadacitinib, but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

This organisation can give you advice and support: [National Axial Spondyloarthritis Society \(NASS\)](#), 0208 741 1515.

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4980-9